This 88-hour on-demand conference includes 64 sessions highlighting best practices and the latest science, research, and innovations in addiction medicine from leading experts in the field.

This 60-minute on-demand session from the ASAM 57th Annual Conference addresses long-acting injectable buprenorphine implementation in criminal justice settings, exploring evidence, challenges, and program development strategies.

This 75-minute on-demand session from the ASAM 57th Annual Conference addresses novel kratom-derived products including 7-OH and kava, covering pharmacology, clinical assessment, and evolving regulatory landscapes.

This 1 hour and 45-minute on-demand session from the ASAM 57th Annual Conference addresses benzodiazepine management in outpatient settings, applying ASAM guidelines to cases and exploring tapering strategies and success definitions.

This 75-minute on-demand session from the ASAM 57th Annual Conference addresses substance use disorders in transplant candidates and recipients, covering evaluation approaches, multidisciplinary care, and long-term outcome strategies.

This 75-minute on-demand session from the ASAM 57th Annual Conference addresses medication call backs in MOUD programs, balancing diversion control strategies with patient-centered and equitable treatment access approaches.

This 75-minute on-demand session from the ASAM 57th Annual Conference addresses co-occurring alcohol use disorder and psychiatric conditions, covering diagnostic tools, integrated treatment plans, and barrier-reduction strategies.

This 75-minute on-demand session from the ASAM 57th Annual Conference addresses pain optimization in opioid-tolerant patients, covering basal-bolus approaches, MOUD in perioperative settings, and multimodal therapies.

This one-hour, journal article–based activity explores key clinical predictors of treatment success for methamphetamine use disorder (MUD) by analyzing secondary data from the landmark ADAPT-2 trial. The article examines how patient levels of craving and impulsivity correlate with transitions between positive and negative urine drug screens (UDS) in individuals receiving a combination of injectable naltrexone and oral bupropion. These findings provide insights for clinicians aiming to optimize pharmacotherapy outcomes and tailor interventions for a high-risk population currently lacking FDA-approved medication options.

Advanced Buprenorphine Education: Best Practices and Interactive Patient Cases is a 4-hour self-paced course that equips clinicians with the latest evidence and practical tools for optimizing buprenorphine treatment in opioid use disorder (OUD).